(Q38355560)

reason for preferred rank

2 September 2017

title

Recognition of DNA modified by antitumor cisplatin by “latent” and “active” protein p53 (English)

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

24 December 2023

Recognition of DNA modified by antitumor cisplatin by "latent" and "active" protein p53 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694871

24 December 2023

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

24 December 2023

Borivoj Vojtesek

1 reference

2 September 2017

Sarka Pospisilova

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694871

24 December 2023

Viktor Brabec

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694871

24 December 2023

Miroslav Fojta

1 reference

2 September 2017

Hana Pivonkova

1 reference

2 September 2017

Marie Brazdova

1 reference

2 September 2017

Lucie Kovarova

1 reference

2 September 2017

Emil Palecek

1 reference

2 September 2017

Jana Kasparkova

1 reference

2 September 2017

Borivoj Vojtesek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694871

24 December 2023

language of work or name

English

0 references

publication date

1 April 2003

1 reference

2 September 2017

15 April 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12694871

full work available at URL

24 December 2023

https://api.elsevier.com/content/article/PII:S0006295203000789?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

https://api.elsevier.com/content/article/PII:S0006295203000789?httpAccept=text/plain

24 December 2023

1 reference

DOI

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

24 December 2023

published in

Biochemical Pharmacology

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

1305-1316

1 reference

p53, the cellular gatekeeper for growth and division

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Mechanisms of p53-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

The role of p53 in tumour suppression: lessons from mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Functions of the MDM2 oncoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

p53 domains: structure, oligomerization, and transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

p53 Protein exhibits 3'-to-5' exonuclease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Binding of p53 and its core domain to supercoiled DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Tumor suppressor protein p53 binds preferentially to supercoiled DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Effect of p53 protein redox states on binding to supercoiled and linear DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Specific modulation of p53 binding to consensus sequence within supercoiled DNA by monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Mechanisms of switching on p53: a role for covalent modification?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Covalent and noncovalent modifiers of the p53 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Post-translational modifications and activation of p53 by genotoxic stresses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

p53 binds to cisplatin-damaged DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Different recognition of DNA modified by aatitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Polarographic Determination of Subnanogram Quantities of Free Platinum in Reaction Mixture with Dna

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Regulation of the specific DNA binding function of p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Multisite phosphorylation and the integration of stress signals at p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Small peptides activate the latent sequence-specific DNA binding function of p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

How p53 binds DNA as a tetramer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Phosphorylation of the C-terminal sites of human p53 reduces non-sequence-specific DNA binding as modeled with synthetic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Effects of Oxidation Agents and Metal Ions on Binding of p53 to Supercoiled DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Induction of Mdm2 and enhancement of cell survival by bFGF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2803%2900078-9

inferred from DOI database lookup

7 January 2021

based on heuristic

The dual role of mutant p53 protein in chemosensitivity of human cancers

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

DNA binding activities of p53 protein following cisplatin damage of ovarian cells

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0006-2952(03)00078-9

24 December 2023

Identifiers

DOI

1 reference

2 September 2017

1 reference